Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Receivables: 2023-2025

Historic Change in Receivables for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to -$3,000.

  • Inhibrx Biosciences' Change in Receivables rose 99.61% to -$3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $728,000, marking a year-over-year increase of 2933.33%. This contributed to the annual value of -$381,000 for FY2024, which is 171.21% down from last year.
  • Latest data reveals that Inhibrx Biosciences reported Change in Receivables of -$3,000 as of Q3 2025, which was down 100.34% from $872,000 recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Change in Receivables registered a high of $872,000 during Q2 2025, and its lowest value of -$768,000 during Q3 2024.
  • Its 3-year average for Change in Receivables is $84,000, with a median of $4,000 in 2023.
  • Per our database at Business Quant, Inhibrx Biosciences' Change in Receivables plummeted by 19,300.00% in 2024 and then surged by 429.06% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Change in Receivables stood at $447,000 in 2023, then tumbled by 90.60% to $42,000 in 2024, then spiked by 99.61% to -$3,000 in 2025.
  • Its Change in Receivables stands at -$3,000 for Q3 2025, versus $872,000 for Q2 2025 and -$183,000 for Q1 2025.